After 20 Years and Hundreds of Compounds, One Drug Keeps Winning: Rapamycin

Two Decades, 54 Compounds, One Clear Winner: Rapamycin

The National Institute on Aging's Interventions Testing Program launched in 2004 with a simple mission: find what actually extends lifespan. Twenty years and 54 tested molecules later, the answer is consistent. Rapamycin is the single most reliable lifespan extender across sexes, associated with a roughly 15–20% increase in longevity in mice. No other compound matches its reliability across sex, age of initiation, and dosage strategies.

Most candidates flopped or helped only one sex. The compounds that worked shared a pattern: they targeted metabolic resilience, stress response, immunity, or inflammation. SGLT2 inhibitors improved longevity by 13.6% in male mice. But the biggest signal came from combinations — rapamycin stacked with acarbose produced up to a 36.6% increase in median lifespan, outperforming either drug alone. That finding is now reshaping how researchers think about multi-pathway aging interventions.

The ITP review, published in the Journal of Gerontology, synthesized two decades of work and will likely guide longevity drug development for the next decade. Researchers are already moving findings into human trials. The PEARL trial tested low-dose weekly rapamycin in healthy adults aged 50–85 over 48 weeks, finding lean mass gains in women and a favorable safety profile. Translation from mice to humans is never clean — but the pipeline from lab to clinic is moving faster than it ever has.

Gobble's Take: Twenty years of rigorous animal data plus a human trial showing real safety and muscle benefits makes rapamycin the most evidence-backed longevity drug you've probably never discussed with your doctor.

Source: Healthspan

Researchers Define a New Category: "Longevity Cosmeceuticals" — and Set a High Bar for What Qualifies

The term "longevity cosmeceuticals" has been circulating in industry and marketing, but until now it had no peer-reviewed scientific definition. A new review article changes that. The authors propose a formal category: skincare products that don't just mask aging signs but target the molecular hallmarks of aging itself — and must prove it through clinical trials.

The definition comes with three strict criteria. A longevity cosmeceutical active must directly target and modulate established hallmarks of skin aging. It must demonstrably extend "skinspan" — a term the authors introduce to capture improvements in skin viability, structure, and functional integrity over time. And its efficacy must be validated through clinical trials, ideally with post-trial skin biopsies to evaluate aging biomarkers, alongside full safety assessments. The authors are explicit: this framework is designed to separate scientifically validated products from marketing-driven claims.

The review also highlights geroprotective compounds — substances shown to extend healthspan and lifespan in animal models — as candidates for cosmeceutical applications. It maps these against twelve recognized hallmarks of skin aging, from oxidative stress to cellular senescence, and recommends specific biomarkers for assessing biological aging in skin. The goal is to push the cosmetic industry toward interventions that produce measurable biological improvements, not just cosmetic ones.

Gobble's Take: If this framework sticks, the skincare industry's vague "anti-aging" claims just got a scientific standard to actually meet.

Source: PMC Cosmeceuticals

Scientists Have Named 9 Reasons You Age — and They're Building Drugs for Each One

Researchers have identified nine interrelated hallmarks of aging, emerging from an understanding of cellular homeostasis and senescence. The list includes genomic instability, telomere attrition, epigenetic alterations, loss of proteostasis, mitochondrial dysfunction, deregulated nutrient sensing, cellular senescence, stem cell exhaustion, and altered intercellular communication. These nine hallmarks are correlated and provide a framework for pharmacological intervention — and that's exactly what geroscience is now pursuing.

Geroscience focuses on targeting the biological mechanisms of aging to delay or prevent age-related diseases. Researchers classify current pharmacotherapeutic strategies into five broad categories: senolytics, senomorphics, NAD+ precursors, mTOR inhibitors, and metabolic modifiers. Senolytics target senescent cells — those that stop dividing but release inflammatory signals through what's known as the senescence-associated secretory phenotype (SASP). Rapamycin inhibits mTOR, a key nutrient-sensing pathway. Metformin acts as a metabolic modifier. NAD+ precursors target the energy metabolism decline that accompanies aging.

The field isn't just theoretical. Researchers are actively reviewing preclinical evidence and translational potential, while clinical trials are underway. Key challenges remain: biomarker identification, safety concerns, and regulatory hurdles. But the conceptual shift is real — aging is being treated as a set of targetable biological mechanisms, not inevitable decline.

Gobble's Take: Nine named problems with named drug candidates means aging research has entered engineering territory — and that changes everything about how we should think about preventive health.

Source: PMC Pharmacological

The Most Promising Longevity Breakthroughs of 2025, Ranked

2025 was a landmark year for longevity science. Researchers didn't just theorize — they published human trial data. The National Institute of Aging's Interventions Testing Program (ITP), now two decades in, has tested 54 molecules for lifespan extension. The verdict: rapamycin is the single most reliable lifespan extender across sexes in mammals, associated with roughly a 15–20% increase in longevity in mice. Combination therapy pushed that further — rapamycin plus acarbose produced up to a 36.6% increase in median lifespan, outperforming either intervention alone.

Human trials are now catching up. The PEARL trial — a 48-week, double-blind, randomized controlled study in healthy adults aged approximately 50–85 — tested once-weekly low-dose rapamycin. Women taking 10 mg showed a 6% increase in lean tissue mass from baseline, plus self-reported improvements in pain and general health. Safety data showed no increase in serious adverse events versus placebo. Separately, a pilot study found that just 1 mg of rapamycin daily for 8 weeks improved diastolic heart function and reduced arterial stiffness in older men. Other highlights: SGLT2 inhibitors improved longevity by 13.6% in male mice, and the FDA removed the black box warning on hormone replacement therapies — a signal that institutional acceptance of longevity interventions is growing.

The decade of healthy aging is half over. The science is moving faster than most people realize.

Gobble's Take: The gap between what longevity researchers know and what your doctor will prescribe has never been wider — and that gap is costing years.

Source: Healthspan

In Case You Missed It

Yesterday's top stories:

• Rapamycin Matches Calorie Restriction — and Starts Working in Hours, Not Months
• The Man Who Trains Tour de France Champions Says the Longevity Industry Is Selling You Anxiety Relief
• NAD+ Drops 50% by Age 50 — Here's the Cheapest Way to Push Back
• A Strawberry Compound Is Clearing Zombie Cells as Effectively as Drugs That Cost Thousands